PACIRA BIOSCIENCES INC (PCRX) Fundamental Analysis & Valuation
NASDAQ:PCRX • US6951271005
22.58 USD
+0.34 (+1.53%)
Last: Mar 10, 2026, 12:50 PM
This PCRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
PCRX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of PCRX get a neutral evaluation. Nothing too spectacular is happening here. PCRX is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make PCRX suitable for value investing!
1. PCRX Profitability Analysis
1.1 Basic Checks
- In the past year PCRX was profitable.
- In the past year PCRX had a positive cash flow from operations.
- Of the past 5 years PCRX 4 years were profitable.
- In the past 5 years PCRX always reported a positive cash flow from operatings.
1.2 Ratios
- Looking at the Return On Assets, with a value of 0.56%, PCRX is in the better half of the industry, outperforming 79.27% of the companies in the same industry.
- PCRX has a better Return On Equity (1.01%) than 81.35% of its industry peers.
- The Return On Invested Capital of PCRX (2.67%) is better than 80.31% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for PCRX is significantly below the industry average of 13.09%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.56% | ||
| ROE | 1.01% | ||
| ROIC | 2.67% |
ROA(3y)-1.06%
ROA(5y)-0.04%
ROE(3y)-2.32%
ROE(5y)0.17%
ROIC(3y)4.67%
ROIC(5y)4.88%
1.3 Margins
- The Profit Margin of PCRX (0.97%) is better than 79.27% of its industry peers.
- PCRX's Profit Margin has declined in the last couple of years.
- PCRX has a Operating Margin of 5.33%. This is in the better half of the industry: PCRX outperforms 79.27% of its industry peers.
- In the last couple of years the Operating Margin of PCRX has declined.
- PCRX has a Gross Margin of 79.39%. This is amongst the best in the industry. PCRX outperforms 84.46% of its industry peers.
- PCRX's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.33% | ||
| PM (TTM) | 0.97% | ||
| GM | 79.39% |
OM growth 3Y-20.59%
OM growth 5Y-17.68%
PM growth 3Y-25.95%
PM growth 5Y-50.88%
GM growth 3Y4.23%
GM growth 5Y1.78%
2. PCRX Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PCRX is destroying value.
- Compared to 1 year ago, PCRX has less shares outstanding
- PCRX has less shares outstanding than it did 5 years ago.
- PCRX has a better debt/assets ratio than last year.
2.2 Solvency
- PCRX has an Altman-Z score of 1.81. This is a bad value and indicates that PCRX is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 1.81, PCRX is in the better half of the industry, outperforming 61.66% of the companies in the same industry.
- PCRX has a debt to FCF ratio of 2.72. This is a good value and a sign of high solvency as PCRX would need 2.72 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 2.72, PCRX belongs to the top of the industry, outperforming 91.71% of the companies in the same industry.
- A Debt/Equity ratio of 0.54 indicates that PCRX is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.54, PCRX is doing worse than 62.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | 2.72 | ||
| Altman-Z | 1.81 |
ROIC/WACC0.32
WACC8.42%
2.3 Liquidity
- PCRX has a Current Ratio of 4.54. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
- PCRX has a better Current ratio (4.54) than 62.69% of its industry peers.
- PCRX has a Quick Ratio of 3.28. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
- PCRX has a Quick ratio of 3.28. This is comparable to the rest of the industry: PCRX outperforms 56.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.54 | ||
| Quick Ratio | 3.28 |
3. PCRX Growth Analysis
3.1 Past
- PCRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.07%.
- Measured over the past 5 years, PCRX shows a small growth in Earnings Per Share. The EPS has been growing by 3.64% on average per year.
- The Revenue for PCRX has decreased by -16.32% in the past year. This is quite bad
- PCRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.08% yearly.
EPS 1Y (TTM)-18.07%
EPS 3Y0.51%
EPS 5Y3.64%
EPS Q2Q%-37.36%
Revenue 1Y (TTM)-16.32%
Revenue growth 3Y2.9%
Revenue growth 5Y11.08%
Sales Q2Q%5.14%
3.2 Future
- PCRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.64% yearly.
- The Revenue is expected to grow by 5.42% on average over the next years.
EPS Next Y16.65%
EPS Next 2Y20.6%
EPS Next 3Y14.23%
EPS Next 5Y10.64%
Revenue Next Year7.11%
Revenue Next 2Y8.4%
Revenue Next 3Y7.67%
Revenue Next 5Y5.42%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. PCRX Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 8.59 indicates a reasonable valuation of PCRX.
- Based on the Price/Earnings ratio, PCRX is valued cheaply inside the industry as 92.23% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Earnings ratio of 26.45, PCRX is valued rather cheaply.
- With a Price/Forward Earnings ratio of 7.36, the valuation of PCRX can be described as very cheap.
- Based on the Price/Forward Earnings ratio, PCRX is valued cheaper than 92.75% of the companies in the same industry.
- PCRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.65.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.59 | ||
| Fwd PE | 7.36 |
4.2 Price Multiples
- 92.23% of the companies in the same industry are more expensive than PCRX, based on the Enterprise Value to EBITDA ratio.
- PCRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PCRX is cheaper than 94.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.69 | ||
| EV/EBITDA | 7.36 |
4.3 Compensation for Growth
- PCRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- PCRX has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as PCRX's earnings are expected to grow with 14.23% in the coming years.
PEG (NY)0.52
PEG (5Y)2.36
EPS Next 2Y20.6%
EPS Next 3Y14.23%
5. PCRX Dividend Analysis
5.1 Amount
- PCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PCRX Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:PCRX (3/10/2026, 12:50:36 PM)
22.58
+0.34 (+1.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26 2026-02-26/amc
Earnings (Next)05-06 2026-05-06
Inst Owners118.41%
Inst Owner Change-2.59%
Ins Owners1.78%
Ins Owner Change16.65%
Market Cap914.26M
Revenue(TTM)726.41M
Net Income(TTM)7.03M
Analysts76.92
Price Target30.31 (34.23%)
Short Float %19.56%
Short Ratio8.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.46%
Min EPS beat(2)-38.21%
Max EPS beat(2)5.28%
EPS beat(4)3
Avg EPS beat(4)-7.2%
Min EPS beat(4)-38.21%
Max EPS beat(4)5.28%
EPS beat(8)6
Avg EPS beat(8)1.27%
EPS beat(12)7
Avg EPS beat(12)-1.33%
EPS beat(16)7
Avg EPS beat(16)-6.57%
Revenue beat(2)0
Avg Revenue beat(2)-3.64%
Min Revenue beat(2)-3.7%
Max Revenue beat(2)-3.59%
Revenue beat(4)0
Avg Revenue beat(4)-4.05%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-2.99%
Revenue beat(8)1
Avg Revenue beat(8)-2.33%
Revenue beat(12)1
Avg Revenue beat(12)-2.76%
Revenue beat(16)1
Avg Revenue beat(16)-2.75%
PT rev (1m)0%
PT rev (3m)-1.5%
EPS NQ rev (1m)-14.02%
EPS NQ rev (3m)-17.67%
EPS NY rev (1m)-11.73%
EPS NY rev (3m)-10.78%
Revenue NQ rev (1m)-3.31%
Revenue NQ rev (3m)-3.43%
Revenue NY rev (1m)-1.07%
Revenue NY rev (3m)-2.25%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.59 | ||
| Fwd PE | 7.36 | ||
| P/S | 1.26 | ||
| P/FCF | 6.69 | ||
| P/OCF | 6.02 | ||
| P/B | 1.32 | ||
| P/tB | 3 | ||
| EV/EBITDA | 7.36 |
EPS(TTM)2.63
EY11.65%
EPS(NY)3.07
Fwd EY13.59%
FCF(TTM)3.38
FCFY14.95%
OCF(TTM)3.75
OCFY16.62%
SpS17.94
BVpS17.12
TBVpS7.53
PEG (NY)0.52
PEG (5Y)2.36
Graham Number31.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.56% | ||
| ROE | 1.01% | ||
| ROCE | 3.38% | ||
| ROIC | 2.67% | ||
| ROICexc | 3.38% | ||
| ROICexgc | 5.91% | ||
| OM | 5.33% | ||
| PM (TTM) | 0.97% | ||
| GM | 79.39% | ||
| FCFM | 18.81% |
ROA(3y)-1.06%
ROA(5y)-0.04%
ROE(3y)-2.32%
ROE(5y)0.17%
ROIC(3y)4.67%
ROIC(5y)4.88%
ROICexc(3y)6.66%
ROICexc(5y)7.23%
ROICexgc(3y)14.37%
ROICexgc(5y)26.99%
ROCE(3y)5.91%
ROCE(5y)6.18%
ROICexgc growth 3Y-17.07%
ROICexgc growth 5Y-17.82%
ROICexc growth 3Y-9.16%
ROICexc growth 5Y-18.82%
OM growth 3Y-20.59%
OM growth 5Y-17.68%
PM growth 3Y-25.95%
PM growth 5Y-50.88%
GM growth 3Y4.23%
GM growth 5Y1.78%
F-Score8
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | 2.72 | ||
| Debt/EBITDA | 2.87 | ||
| Cap/Depr | 16.85% | ||
| Cap/Sales | 2.11% | ||
| Interest Coverage | 2.54 | ||
| Cash Conversion | 117.14% | ||
| Profit Quality | 1942.86% | ||
| Current Ratio | 4.54 | ||
| Quick Ratio | 3.28 | ||
| Altman-Z | 1.81 |
F-Score8
WACC8.42%
ROIC/WACC0.32
Cap/Depr(3y)16.8%
Cap/Depr(5y)48.87%
Cap/Sales(3y)1.96%
Cap/Sales(5y)3.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.07%
EPS 3Y0.51%
EPS 5Y3.64%
EPS Q2Q%-37.36%
EPS Next Y16.65%
EPS Next 2Y20.6%
EPS Next 3Y14.23%
EPS Next 5Y10.64%
Revenue 1Y (TTM)-16.32%
Revenue growth 3Y2.9%
Revenue growth 5Y11.08%
Sales Q2Q%5.14%
Revenue Next Year7.11%
Revenue Next 2Y8.4%
Revenue Next 3Y7.67%
Revenue Next 5Y5.42%
EBIT growth 1Y-65.3%
EBIT growth 3Y-18.29%
EBIT growth 5Y-8.56%
EBIT Next Year17.68%
EBIT Next 3Y14.84%
EBIT Next 5Y7.61%
FCF growth 1Y-23.55%
FCF growth 3Y5.86%
FCF growth 5Y28.37%
OCF growth 1Y-19.75%
OCF growth 3Y1.51%
OCF growth 5Y14.57%
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
What is the valuation status for PCRX stock?
ChartMill assigns a valuation rating of 9 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 6 / 10.
What is the valuation of PACIRA BIOSCIENCES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 8.59 and the Price/Book (PB) ratio is 1.32.